Concern over NSW indemnity insurance impact on clinical trials prompts survey
Members of AusBiotech are invited to participate in a survey to gauge the impact of the 2011 increase in the Clinical Trial Indemnity Insurance Compliance Requirement. The increase doubled the minimum requirement for indemnity insurance from $10 million to $20 million, putting it at odds with the rest of the country and giving NSW the highest compulsory limits in the world.
The survey is seeking comment on how the increase is impacting NSW and Australia's overall ability to be internationally and nationally competitive. Through completing the short questionnaire, you may assist the NSW Branch Committee of AusBiotech to make a case to NSW Health to reconsider and return to a $10 million minimum requirement.
To complete the survey, click here. It is open until 31 May 2013.
Moves to follow NSW surfaced in other states in 2012; however, none have done so to date. Victoria opposed the move last year.
For more information, contact
AusBiotech Communications Manager Lorraine Chiroiu on 03 9828 1414 or lchiroiu@ausbiotech.org.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
